Compare WAFU & ALBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WAFU | ALBT |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2M | 5.9M |
| IPO Year | 2019 | N/A |
| Metric | WAFU | ALBT |
|---|---|---|
| Price | $1.67 | $0.77 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.0K | ★ 123.7K |
| Earning Date | 07-31-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,186,645.00 | $1,611,940.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.22 | $0.75 |
| 52 Week High | $7.49 | $11.66 |
| Indicator | WAFU | ALBT |
|---|---|---|
| Relative Strength Index (RSI) | 67.70 | 26.94 |
| Support Level | $1.65 | $0.75 |
| Resistance Level | $1.81 | $1.19 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 82.86 | 2.15 |
Wah Fu Education Group Ltd is involved in providing online exam preparation services and related technology solutions, and also produces online training course materials in China. It develops online educational materials that are offered through the cloud and that can be used for a wide range of purposes, such as standard examination preparation, professional training, and interactive programs for educational purposes other than exam preparation. Its segments are Online Education Services and Technological Development and Operation Service. The company generates maximum revenue from the Online Education Services segment.
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment, which is the key revenue driver, and the laboratory testing services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.